Equities research analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to post sales of $33.58 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Oxford Immunotec Global’s earnings. The highest sales estimate is $33.74 million and the lowest is $33.39 million. Oxford Immunotec Global posted sales of $30.43 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.4%. The firm is scheduled to announce its next earnings report on Tuesday, October 30th.

On average, analysts expect that Oxford Immunotec Global will report full year sales of $113.16 million for the current year, with estimates ranging from $112.82 million to $113.60 million. For the next financial year, analysts anticipate that the business will report sales of $127.61 million per share, with estimates ranging from $125.28 million to $129.54 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its earnings results on Tuesday, July 31st. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.25). Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. The business had revenue of $29.32 million for the quarter, compared to analyst estimates of $28.58 million. During the same quarter last year, the business earned ($0.74) earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year.

OXFD has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Friday, June 1st. BidaskClub upgraded shares of Oxford Immunotec Global from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 31st. Finally, ValuEngine lowered shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Two research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $17.80.

Shares of NASDAQ OXFD traded up $0.28 during trading on Monday, hitting $15.03. The company had a trading volume of 238,403 shares, compared to its average volume of 65,479. Oxford Immunotec Global has a fifty-two week low of $10.00 and a fifty-two week high of $17.41. The firm has a market cap of $383.02 million, a price-to-earnings ratio of -11.05 and a beta of -0.20. The company has a quick ratio of 4.86, a current ratio of 5.39 and a debt-to-equity ratio of 0.41.

In related news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $13.15, for a total transaction of $39,450.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 6.61% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Redmile Group LLC boosted its position in Oxford Immunotec Global by 6.5% during the first quarter. Redmile Group LLC now owns 2,469,687 shares of the company’s stock worth $30,748,000 after acquiring an additional 151,300 shares during the last quarter. BlackRock Inc. boosted its holdings in Oxford Immunotec Global by 10.0% in the 2nd quarter. BlackRock Inc. now owns 1,279,324 shares of the company’s stock valued at $16,490,000 after purchasing an additional 116,814 shares during the last quarter. First Light Asset Management LLC boosted its holdings in Oxford Immunotec Global by 98.0% in the 2nd quarter. First Light Asset Management LLC now owns 1,240,391 shares of the company’s stock valued at $15,989,000 after purchasing an additional 613,806 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in Oxford Immunotec Global by 18.6% in the 2nd quarter. Wasatch Advisors Inc. now owns 883,761 shares of the company’s stock valued at $11,392,000 after purchasing an additional 138,571 shares during the last quarter. Finally, Granahan Investment Management Inc. MA boosted its holdings in Oxford Immunotec Global by 9.1% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 565,332 shares of the company’s stock valued at $7,287,000 after purchasing an additional 47,159 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Recommended Story: Asset Allocation

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.